Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Alan S. Coates, Binghe Xu, Andrew Tutt et al.|Annals of Oncology|2015Cited by 1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Dennis J. Slamon, Nicholas C. Turner et al.|The Lancet Oncology|2016Cited by 1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNicholas C. Turner, Massimo Cristofanilli, Dennis J. Slamon et al.|New England Journal of Medicine|2018Cited by 1.3k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Giuseppe Curigliano, Andrew Tutt, Harold J. Burstein et al.|Annals of Oncology|2017Cited by 1.3k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock‐Ah Im, Debu Tripathy, Yen‐Shen Lu et al.|New England Journal of Medicine|2019Cited by 1k